source
- Lonza plans new ADC manufacturing site and workforce boost to capture commercial marketLonza said it aims to become a leading supplier of antibody-drug conjugates (ADCs) for commercial use. The Swiss contract manufacturing organization highlighted the growing demand for ADCs and its…
- CellCentric secures $220 million Series D to advance multiple myeloma oral therapyCellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round. The capital will be used to complete development and prepare for…